Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.56 |
| ▸ | PDE4A | P27815 | 10/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585249 | 1.00 | PDE4B (0.56) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15869361 | 1.00 | PDE4B (0.56) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL17085033 | 1.00 | PDE4B (0.56) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15862507 | 1.00 | PDE4B (0.56) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15869366 | 1.00 | PDE4B (0.56) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15869358 | 0.90 | PDE4B (0.48) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1826156 | 0.87 | TNF (0.48) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1826154 | 0.87 | TNF (0.48) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15869360 | 0.87 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15862397 | 0.87 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651400-B2 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF | AMGEN EUROPE GMBH (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-3142748-B1 | USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CELGENE CORP (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2651400-B1 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF | CELGENE CORP (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3373916-A1 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF | Celgene Corporation (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-2701701-B1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | CELGENE CORP (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-2663292-B9 | ORAL DOSAGE FORMS OF CYCLOPROPANECARBOXYLIC ACID {2-[(1S)-1-(3-ETHOXY-4-METHOXY-PHENYL]-2-METHANESULFONYL-ETHYL]-3-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | CELGENE CORP (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9757355-B2 | Oral dosage forms of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide | CELGENE CORPORATION (US) | 2017-09-12 | — | — | US | disclosed |
| WO-2017083348-A1 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF | CELGENE CORPORATION (US) | 2017-05-18 | — | — | WO | disclosed |
| EP-2663292-B1 | ORAL DOSAGE FORMS OF CYCLOPROPANECARBOXYLIC ACID {2-[(1S)-1-(3-ETHOXY-4-METHOXY-PHENYL]-2-METHANESULFONYL-ETHYL]-3-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | CELGENE CORP (US) | 2017-05-10 | — | — | EP | disclosed |
| US-9642836-B2 | Isotopologues of isoindole derivatives | CELGENE CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-20140018404-A1 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF | CELGENE CORPORATION (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2486012-B1 | PROCESSES FOR THE PREPARATION OF 2-(1-PHENYLETHYL) ISOINDOLIN-1-ONE COMPOUNDS | CELGENE CORP (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130116204-A1 | (METHYLSULFONYL) ETHYL BENZENE ISOINDOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-8415485-B2 | Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds | CELGENE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415485-B2 | Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds | CELGENE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415485-B2 | Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds | CELGENE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120276087-A1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | AMGEN INC. | 2012-11-01 | — | — | US | disclosed |
| US-20110087033-A1 | Processes for the Preparation of 2-(1-Phenylethyl)isoindolin-1-one Compounds | AMGEN INC. | 2011-04-14 | — | — | US | disclosed |
| US-20110087033-A1 | Processes for the Preparation of 2-(1-Phenylethyl)isoindolin-1-one Compounds | AMGEN INC. | 2011-04-14 | — | — | US | disclosed |
| US-20100129363-A1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF CANCERS | CELGENE CORPORATION | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087033-A1 | Processes for the Preparation of 2-(1-Phenylethyl)isoindolin-1-one Compounds | PNMT, CYP2E1, CYP1A1 | PDE4B 2125/4885PDE4C 2410/4885PDE4A 2697/4885 |
| US-20140018404-A1 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF | ABCB11, SUCNR1, SI | PDE4B 1070/4885PDE4C 1604/4885PDE4A 748/4885 |
| US-20100129363-A1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF CANCERS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4C 3/4885PDE4A 1/4885 |
| US-20130116204-A1 | (METHYLSULFONYL) ETHYL BENZENE ISOINDOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | ABCG2, TPMT, CYP2D6 | PDE4B 1179/4885PDE4C 1536/4885PDE4A 1328/4885 |
| US-20120276087-A1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4C 3/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.